Thermo Fisher Sells Its Anatomical Pathology Business

Thermo Fisher Sells Its Anatomical Pathology Business

by | Jan 31, 2019 12:15 pm | Laboratories, MRI & Dialysis | 0 comments

Shortly before it reported fourth quarter and full-year earnings results, Thermo Fisher Scientific (NYSE: TMO) announced the sale of its anatomical pathology (AP) business for $1.14 billion. The buyer, Tokyo-based PHC Holdings Corporation, is a global healthcare company developing and manufacturing medical equipment and products across diabetes care, diagnostics, life sciences and healthcare information technology. Its consolidated net sales in FY2017 was approximately $1.76 billion. The AP business provides microscope slides, instruments and consumables. It has approximately 1,200 employees at locations in the U.S., Europe and China. The business generates approximately $350 million in... Read More »
Merit Medical Scores Assets from BD and Bard

Merit Medical Scores Assets from BD and Bard

by | Nov 17, 2017 5:13 pm | Medical Devices | 0 comments

Just after the release of the third quarter results, Merit Medical Systems, Inc. (NASDAQ: MMSI) announced an asset purchase agreement with two of its competitors. Merit has made two other similar acquisitions in 2017. The company entered into an asset purchase agreement with Becton, Dickinson and Company (NYSE: BDX) and C.R. Bard, Inc. (NYSE: BCR) to acquire various assets in relation to BD’s $24 billion acquisition of C.R. Bard, announced on April 23, 2017. The acquired assets include soft tissue core needle biopsy products currently sold by BD under the trade names of Achieve™ Programmable Automatic Biopsy System, Temno™ Biopsy System and Tru-Cut™ Biopsy Needles, which are currently sold... Read More »

Medical Device Sector Is Most Active in H1:17

by | Jul 14, 2017 4:11 pm | Medical Devices | 0 comments

The Medical Device sector has been humming. Granted, it comprises a huge range of things, from hip and knee joints to cardiovascular devices. Since 2016, 176 deals have been announced, and $102 billion has been committed based on 73 disclosed prices. Among the 176 deals, 14 target companies specialize in cardiovascular devices, 14 specialize in orthopedic and spine devices, 10 specialize in aesthetic devices each, and eight specialize in vascular devices, to name a few. The most recent deal, on July 10, was of a company that covered a very interesting niche of medical devices. ThermoGenesis Corp., a wholly-owned subsidiary of Cesca Therapeutics Inc., (NASDAQ: KOOL) acquired privately held... Read More »

Spending on Health Care Deals Popped in April

by | May 12, 2017 3:05 pm | Medical Devices | 0 comments

April deal volume disappointed, with 103 deals and a decrease of 29% compared with March 2017 (145 deals). On the spending side, April’s preliminary spending total increased 931% compared with the previous month’s $4.8 billion. Here’s the breakdown. April’s combined spending hit $49.9 billion, which was 15% higher than the total in April 2016. This month’s high was the result of a single large deal, the $24 billion spent by Becton, Dickinson and Company (NYSE: BDX) for C.R. Bard (NYSE: CBR), in the Medical Device sector. Also worth noting is the more than $9.0 billion spent by Hellman & Friedman to buy out the majority stake owned partner, The Carlyle Group (NYSE:... Read More »

Becton, Dickinson Leads the Medical Device Sector

by | Apr 26, 2017 7:40 pm | Medical Devices | 0 comments

The Medical Device sector isn’t seeing a flood of deals, but the dollars are adding up fast. In the first four months of 2017, dollars committed to deals in this sector have reached 60% of 2016’s total of $61.6 billion. With just 31 deals announced, deal volume stands at 27% of last year’s total of 112 transactions. Four deals have surpassed the $1 billion mark this year, and one currently accounts for 65% of this year’s $36.9 billion total. That deal, recently announced, is Becton, Dickinson and Company’s (NYSE: BDX) $24 billion purchase of C.R. Bard, Inc. (NYSE: BCR). In late April, Becton, Dickinson (BD) announced it would pay $317.00 per share for the New Jersey-based... Read More »